Prosecution Insights
Prosecution Insights
15 pending office actions • 11 art units • 13 examiners • 0 of 15 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 9 (60%) |
| §102 only | 1 (7%) |
| No statute on record | 5 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JAVANMARD, SAHAR | 3 | 65.3% | +35.6% |
| CHANG, KYUNG SOOK | 1 | 60.3% | +41.2% |
| HAVLIN, ROBERT H | 1 | 52.3% | +27.2% |
| REILLY, SOPHIA JANE | 1 | 59.3% | +51.1% |
| BAUER, BRIANNA LEE | 1 | — | — |
| KAPUSHOC, STEPHEN THOMAS | 1 | 46.6% | +52.8% |
| BAEK, JONGHWAN NMN | 1 | 66.7% | +0.0% |
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| PECKHAM, RICHARD GRANT | 1 | 68.3% | +35.6% |
| ISMAIL, REHANA | 1 | 78.9% | +30.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18005868 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CHRNA4 MUTATION | JAVANMARD, SAHAR | 147d overdue |
| 18446405 | CANNABIDIOL PREPARATIONS AND ITS USES | JAVANMARD, SAHAR | 91d overdue |
| 18257373 | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | KIFLE, BRUCK | 74d overdue |
| 18597717 | ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDS | CHANG, KYUNG SOOK | 43d overdue |
| 18256307 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH EPILEPSY SYNDROMES IN PATIENTS TAKING BRIVARACETAM | PECKHAM, RICHARD GRANT | 42d overdue |
| 18044941 | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | ISMAIL, REHANA | 16d overdue |
| 18477467 | PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID | JAVANMARD, SAHAR | 15d overdue |
| 18560316 | 6-HYDROXY-CANNABIDIOL-C4 | HAVLIN, ROBERT H | 8d overdue |
| Art Unit | Apps |
|---|---|
| 1622 | 4 |
| 1627 | 2 |
| 1613 | 1 |
| 1626 | 1 |
| 1623 | 1 |
| 1683 | 1 |
| 1618 | 1 |
| 1624 | 1 |
| 1625 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18597717 | ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDS | CHANG, KYUNG SOOK | 1613 | Other | Non-Final OA | 43d overdue | Pending | Mar 06, 2024 |
| 18560316 | 6-HYDROXY-CANNABIDIOL-C4 | HAVLIN, ROBERT H | 1626 | Other | Non-Final OA | 8d overdue | Pending | Nov 10, 2023 |
| 18560341 | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | REILLY, SOPHIA JANE | 1627 | Other | Non-Final OA | 26d | Pending | Nov 10, 2023 |
| 18477467 | PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID | JAVANMARD, SAHAR | 1622 | §103 | Non-Final OA | 15d overdue | Pending | Sep 28, 2023 |
| 18546254 | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CANINE EPILEPSY | BAUER, BRIANNA LEE | 1623 | Other | Non-Final OA | 20d | Pending | Aug 11, 2023 |
| 18446405 | CANNABIDIOL PREPARATIONS AND ITS USES | JAVANMARD, SAHAR | 1622 | §103 | Non-Final OA | 91d overdue | Pending | Aug 08, 2023 |
| 18258485 | IDENTIFICATION AND TREATMENT OF PATIENTS WITH EPILEPSY | KAPUSHOC, STEPHEN THOMAS | 1683 | §102 | Non-Final OA | 34d | Pending | Jun 20, 2023 |
| 18257479 | A METHOD FOR EVALUATING THE PRO-OR ANTI CONVULSIVE PROPERTIES OF TEST COMPOUNDS | BAEK, JONGHWAN NMN | 1618 | §103 | Non-Final OA | 51d overdue | Pending | Jun 14, 2023 |
| 18257373 | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | KIFLE, BRUCK | 1624 | §103 | Non-Final OA | 74d overdue | Pending | Jun 14, 2023 |
| 18256307 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH EPILEPSY SYNDROMES IN PATIENTS TAKING BRIVARACETAM | PECKHAM, RICHARD GRANT | 1627 | Other | Non-Final OA | 42d overdue | Pending | Jun 07, 2023 |
| 18044941 | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | ISMAIL, REHANA | 1625 | §103 | Non-Final OA | 16d overdue | Pending | Mar 10, 2023 |
| 18006129 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN | RAO, SAVITHA M | 1691 | §103 | Non-Final OA | 127d overdue | Pending | Jan 19, 2023 |
| 18005868 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CHRNA4 MUTATION | JAVANMARD, SAHAR | 1622 | §103 | Non-Final OA | 147d overdue | Pending | Jan 18, 2023 |
| 18005843 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | MERCIER, MELISSA S | 1615 | §103 | Final Rejection | 23d overdue | Pending | Jan 17, 2023 |
| 17786949 | ORAL CANNABINOID FORMULATIONS | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103 | Non-Final OA | 22d overdue | Pending | Jun 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial